

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1639MLS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/Caplus updated with revised CAS roles
NEWS	7	JAN 22	CA/Caplus enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/Caplus Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	33	MAY 21	CA/Caplus enhanced with additional kind codes for German patents
NEWS	34	MAY 22	CA/Caplus enhanced with IPC reclassification in Japanese patents
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1639MLS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS	6	JUL 16	CAPLUS enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPLUS patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPLUS enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPLUS coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS EXPRESS	19	SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:55:49 ON 23 NOV 2007

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 14:57:10 ON 23 NOV 2007

FILE 'BIOSIS' ENTERED AT 14:57:10 ON 23 NOV 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 14:57:10 ON 23 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 14:57:10 ON 23 NOV 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:57:10 ON 23 NOV 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:57:10 ON 23 NOV 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=> cytosol? (s) accessory 5n protein
L1 0 CYTOSOL? (S) ACCESSORY 5N PROTEIN

=> accessory 5n protein
L2 0 ACCESSORY 5N PROTEIN

=> accessory (s) protein
L3 9969 ACCESSORY (S) PROTEIN

=> cytosol? (s) accessory (s) protein
L4 70 CYTOSOL? (S) ACCESSORY (S) PROTEIN

=> membrane and l3
L5 1773 MEMBRANE AND L3

=> membrane and l4
L6 28 MEMBRANE AND L4

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7 12 DUP REM L6 (16 DUPLICATES REMOVED)

=> t ti l7 1-12

L7 ANSWER 1 OF 12 MEDLINE on STN DUPLICATE 1
TI A Ser/Thr kinase required for membrane-associated assembly of the major sperm protein motility apparatus in the amoeboid sperm of Ascaris.

L7 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Docking of cytosolic chaperone-substrate complexes at the membrane

ATPase during flagellar type III protein export

- L7 ANSWER 3 OF 12 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
TI New array comprising surface having an attached cytosolic accessory protein free of its membrane protein components or other sub-units, useful for measuring the relative catalytic activity of accessory proteins
- L7 ANSWER 4 OF 12 MEDLINE on STN DUPLICATE 2
TI Protein-protein, protein-RNA and protein-lipid interactions of signal-recognition particle components in the hyperthermoacidophilic archaeon *Acidianus ambivalens*.
- L7 ANSWER 5 OF 12 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
TI Selectively incorporating a proteinaceous target molecule complex into a virus like particle for screening or purifying recombinant molecules comprises co-expressing target molecules in recombinant cells with signal molecules
- L7 ANSWER 6 OF 12 MEDLINE on STN DUPLICATE 3
TI Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever.
- L7 ANSWER 7 OF 12 MEDLINE on STN DUPLICATE 4
TI Association of the chaperone glucose-regulated protein 58 (GRP58/ER-60/ERp57) with Stat3 in cytosol and plasma membrane complexes.
- L7 ANSWER 8 OF 12 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI Membrane topology of the lactococcal bacteriocin ATP-binding cassette transporter protein LcnC - Involvement of LcnC in lactococcin A maturation
- L7 ANSWER 9 OF 12 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI Interactions of nucleotide release factor Dss4p with Sec4p in the post-Golgi secretory pathway of yeast
- L7 ANSWER 10 OF 12 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI At-GDI1 from *Arabidopsis thaliana* encodes a rab-specific GDP dissociation inhibitor that complements the sec19 mutation of *Saccharomyces cerevisiae*
- L7 ANSWER 11 OF 12 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI The role of *Helicobacter pylori* urease in the pathogenesis of gastritis and peptic ulceration
- L7 ANSWER 12 OF 12 MEDLINE on STN
TI Structural diversity of eukaryotic protein tyrosine phosphatases: functional and evolutionary implications.

=> d ibib abs 17 3

L7 ANSWER 3 OF 12 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-779116 [73] WPIDS
DOC. NO. CPI: C2003-214547 [73]
TITLE: New array comprising surface having an attached cytosolic accessory protein free of its membrane protein

components or other sub-units, useful for measuring the
relative catalytic activity of accessory
proteins

DERWENT CLASS:

B04; D16

INVENTOR:

BLACKBURN J M; DAVIES A; GODBER B L J; HART D J;
KOZLOWSKI R; BLACKBURN J; GODBER B; HART D

PATENT ASSIGNEE:

(BLAC-I) BLACKBURN J M; (KOZL-I) KOZLOWSKI R; (SENS-N)
SENSE PROTEOMIC LTD

COUNTRY COUNT:

102

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003078464	A2	20030925	(200373)*	EN	39[10]	
AU 2003212526	A1	20030929	(200432)	EN		
GB 2402131	A	20041201	(200479)	EN		
EP 1485411	A2	20041215	(200482)	EN		
US 20050181449	A1	20050818	(200555)	EN		
JP 2006501141	W	20060112	(200604)	JA	24	
AU 2003212526	A8	20051027	(200624)	EN		
EP 1485411	B1	20070509	(200732)	EN		
DE 60313750	E	20070621	(200744)	DE		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003078464	A2	WO 2003-GB1049	20030313
AU 2003212526	A1	AU 2003-212526	20030313
AU 2003212526	A8	AU 2003-212526	20030313
EP 1485411	A2	EP 2003-708346	20030313
EP 1485411	B1	EP 2003-708346	20030313
JP 2006501141	W	JP 2003-576468	20030313
GB 2402131	A	WO 2003-GB1049	20030313
EP 1485411	A2	WO 2003-GB1049	20030313
US 20050181449	A1	WO 2003-GB1049	20030313
JP 2006501141	W	WO 2003-GB1049	20030313
EP 1485411	B1	WO 2003-GB1049	20030313
GB 2402131	A	GB 2003-10085	20030501
US 20050181449	A1	US 2005-506756	20050328
DE 60313750	E	DE 2003-613750	20030313
DE 60313750	E	EP 2003-708346	20030313
DE 60313750	E	WO 2003-GB1049	20030313

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 2003212526	A1	Based on	WO 2003078464	A
GB 2402131	A	Based on	WO 2003078464	A
EP 1485411	A2	Based on	WO 2003078464	A
JP 2006501141	W	Based on	WO 2003078464	A
AU 2003212526	A8	Based on	WO 2003078464	A
EP 1485411	B1	Based on	WO 2003078464	A
DE 60313750	E	Based on	EP 1485411	A
DE 60313750	E	Based on	WO 2003078464	A

PRIORITY APPLN. INFO: GB 2002-5910 20020313

GB 2003-10085 20030501

AN 2003-779116 [73] WPIDS

AB WO 2003078464 A2 UPAB: 20060120

NOVELTY - An array comprising a surface having an attached

cytosolic accessory protein that is free of its membrane protein components or other sub-units with which it is normally complexed, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) determining which cytosolic accessory proteins interact with a given membrane protein or vice versa by:

(a) providing the array of candidate cytosolic accessory proteins;
(b) contacting the array with cytosolic fragments of the membrane protein and/or cytosolic fragments of other related membrane protein family membrane; and

(c) detecting and identifying the interacting partners;

(2) screening compounds, peptides or proteins for the ability to interact selectively with a cytosolic accessory protein by:

(a) providing the array of candidate cytosolic accessory proteins;

(b) contacting the array with compounds, peptides or proteins; and

(c) identifying the interacting partners; and

(3) screening compounds, peptides or proteins for the ability to selectively modulate the interaction between a cytosolic accessory protein and a membrane protein by:

(a) providing the array of candidate cytosolic accessory proteins;

and

(b) contacting the array with compounds, peptides or proteins and with one or more membrane proteins or its cytosolic fragments, either simultaneously or in sequence.

USE - The array is useful for measuring the relative catalytic activity of different members of a family of accessory proteins, as an affinity surface on which to select antibodies from a library of phenotype-genotype-linked antibodies, e.g. phage displayed antibodies, and for determining the effect of post-translational modifications on the interactions of accessory proteins with membrane proteins and/or on the properties of the membrane proteins (all claimed).

=> d his

(FILE 'HOME' ENTERED AT 14:55:49 ON 23 NOV 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, SCISEARCH, EMBASE, WPIDS' ENTERED AT 14:57:10 ON 23 NOV 2007

L1 0 CYTOSOL? (S) ACCESSORY 5N PROTEIN
L2 0 ACCESSORY 5N PROTEIN
L3 9969 ACCESSORY (S) PROTEIN
L4 70 CYTOSOL? (S) ACCESSORY (S) PROTEIN
L5 1773 MEMBRANE AND L3
L6 28 MEMBRANE AND L4
L7 12 DUP REM L6 (16 DUPLICATES REMOVED)

=> (array or ?array)

L8 731064 (ARRAY OR ?ARRAY)

=> 14 and 18

L9 1 L4 AND L8

=> 19 not 17

L10 0 L9 NOT L7

=> 13 and 18

L11 197 L3 AND L8

=> membrane and l11
L12 69 MEMBRANE AND L11

=> dup rem l12
PROCESSING COMPLETED FOR L12
L13 49 DUP REM L12 (20 DUPLICATES REMOVED)

=> review and l13
L14 0 REVIEW AND L13

=> review and l11
L15 2 REVIEW AND L11

=> dup rem l15
PROCESSING COMPLETED FOR L15
L16 2 DUP REM L15 (0 DUPLICATES REMOVED)

=> d ibib abs 1-2

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:667920 CAPLUS

DOCUMENT NUMBER: 139:348769

TITLE: Tissue glucocorticoid resistance/hypersensitivity syndromes

AUTHOR(S): Kino, Tomoshige; De Martino, Massimo U.; Charmandari, Evangelia; Mirani, Marco; Chrousos, George P.

CORPORATE SOURCE: National Institute of Child Health and Human Development, Pediatric and Reproductive Endocrinology Branch, National Institutes of Health, Bethesda, MD, 20892-1583, USA

SOURCE: Journal of Steroid Biochemistry and Molecular Biology (2003), 85(2-5), 457-467
CODEN: JSBBEZ; ISSN: 0960-0760

PUBLISHER: : Elsevier Science Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Glucocorticoids have a broad array of life-sustaining functions and play an important role in the therapy of many diseases. Thus, changes of tissue sensitivity to glucocorticoids may be associated with and influence the course and treatment of many pathol. states. Such tissue sensitivity changes may present on either side of an optimal range, resp. as glucocorticoid resistance or hypersensitivity, and may be generalized or tissue-specific. Familial/sporadic glucocorticoid resistance syndrome caused by inactivating mutations of the glucocorticoid receptor (GR) gene is a classic monogenic disorder associated with congenital, generalized glucocorticoid insensitivity, while several autoimmune, inflammatory and allergic diseases are often associated with resistance of the inflamed tissues to glucocorticoids. On the other hand, glucocorticoid hypersensitivity has been suggested in visceral obesity-related insulin resistance associated with components of the metabolic syndrome, and in the acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus type-1 (HIV-1) infection. Here, we have reviewed the mol. analyses of five familial and three sporadic cases of the familial/sporadic glucocorticoid resistance syndrome and discussed the possible contribution of newly identified mol., such as HIV-1 accessory proteins Vpr and Tat, FLICE-associated huge protein (FLASH) and chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), on the mol. regulation of GR activity, as well as their possible contribution to changes in tissue sensitivity to glucocorticoids in pathol. conditions.

REFERENCE COUNT: 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003511557 EMBASE
TITLE: Leukemogenesis of Adult T-Cell Leukemia.
AUTHOR: Yasunaga J.-I.; Matsuoka M.
CORPORATE SOURCE: Dr. J.-I. Yasunaga; Institute for Virus Research, Kyoto University, Kyoto, Japan. jyasunag@virus.kyoto-u.ac.jp
SOURCE: International Journal of Hematology, (Nov 2003) Vol. 78, No. 4, pp. 312-320.
Refs: 97
ISSN: 0925-5710 CODEN: IJHEEY
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
025 Hematology
026 Immunology, Serology and Transplantation
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 16 Jan 2004
Last Updated on STN: 16 Jan 2004

AB Adult T-cell leukemia (ATL) is one of the most aggressive hematologic malignancies and is caused by human T-cell leukemia virus type I (HTLV-I). Tax, encoded by the HTLV-I pX region, has been recognized by its pleiotropic actions as a critical accessory protein playing a central role in leukemogenesis. However, fresh ATL cells frequently lose Tax protein expression via several mechanisms, such as genetic and epigenetic changes in the provirus. Furthermore, there is a long latency period before the onset of ATL, indicating the multistep mechanisms of leukemogenesis. Therefore, additional factors, including other viral proteins, genetic and epigenetic changes of the host genome, and alterations in the gene expression and immune systems of the host cells, may be implicated in ATL leukemogenesis. This review summarizes recent advances in the understanding of ATL leukemogenesis. .COPYRGT. 2003 The Japanese Society of Hematology.

=> d his

(FILE 'HOME' ENTERED AT 14:55:49 ON 23 NOV 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, SCISEARCH, EMBASE, WPIDS' ENTERED AT 14:57:10 ON 23 NOV 2007

L1 0 CYTOSOL? (S) ACCESSORY 5N PROTEIN
L2 0 ACCESSORY 5N PROTEIN
L3 9969 ACCESSORY (S) PROTEIN
L4 70 CYTOSOL? (S) ACCESSORY (S) PROTEIN
L5 1773 MEMBRANE AND L3
L6 28 MEMBRANE AND L4
L7 12 DUP REM L6 (16 DUPLICATES REMOVED)
L8 731064 (ARRAY OR ?ARRAY)
L9 1 L4 AND L8
L10 0 L9 NOT L7
L11 197 L3 AND L8
L12 69 MEMBRANE AND L11
L13 49 DUP REM L12 (20 DUPLICATES REMOVED)
L14 0 REVIEW AND L13
L15 2 REVIEW AND L11
L16 2 DUP REM L15 (0 DUPLICATES REMOVED)

=> l13 t ti 1-49

MISSING OPERATOR L13 T TI

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> t ti l13 1-49

- L13 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Protein biomarkers of cervical dysplasia in humans and their use in diagnosis
- L13 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Cancer serum markers identified for use in hybridization- and amplification-based diagnosis of early stage human breast cancer
- L13 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI A map of human genes and genetic markers associated with Crohn's disease and its diagnostic and pharmacogenetic uses
- L13 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profile for diagnosing small cell lung cancer, discriminating from non-small cell lung cancer, and assessing chemotherapy-resistant lung cancer
- L13 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Diagnosis and prognosis of infectious disease by analysis of gene expression profiles in peripheral blood leukocytes
- L13 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Monitoring of post-operational changes after liver transplantation by gene expression profiling
- L13 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiling in peripheral blood mononuclear cells in the diagnosis and therapy of vascular disease
- L13 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiling in monocytes in the diagnosis of leukemia
- L13 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and atherosclerosis
- L13 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy by gene expression profiling in peripheral blood cells
- L13 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression and protein profiles in tendons and variables affecting them and their use in the diagnosis of connective tissue diseases
- L13 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiles for diagnosis, prognosis and selection of treatment of acute myeloid leukemia
- L13 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Genes showing changes in levels of expression in neurological diseases and their use in early diagnosis and in monitoring of treatment
- L13 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiling of monocytes in differentiation of leukemias associated with translocation (9;22)
- L13 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Arrays of human proteins and their use for identifying binding proteins

and enzyme substrates

- L13 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression and protein profiles in bipolar disorder and major depressive disorder and their use in the diagnosis and treatment of psychiatric disease
- L13 ANSWER 17 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
TI Targeting vector useful in modified artificial chromosome comprises pair of cleavage sites that flank packaging/cleavage site and origin of replication of herpes virus; antibiotic resistance gene; and sequence encoding detectable marker
- L13 ANSWER 18 OF 49 MEDLINE on STN
TI AXR4 is required for localization of the auxin influx facilitator AUX1.
- L13 ANSWER 19 OF 49 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
TI Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10(++)IL-12(low/neg) accessory cells with dendritic-cell features.
- L13 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Analysis of complex gene expression profiles using an analysis of the cellular composition of the sample to identify cell-type-specific signatures
- L13 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiles in the diagnosis and treatment of Alzheimer's disease
- L13 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profile useful for diagnosis and treatment methods related to aging of liver
- L13 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI The curcuminoids- and anthocyanins-responsive genes in human adipocytes and their use in screenings of anti-obesity and anti-diabetes drugs
- L13 ANSWER 24 OF 49 MEDLINE on STN DUPLICATE 1
TI Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2.
- L13 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2
TI Gene expression profiles and biomarkers for the detection of hyperlipidemia and other disease-related gene transcripts in blood
- L13 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
TI Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy
- L13 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Differentially regulated hepatocellular carcinoma genes and protein and DNA arrays for use in diagnosis and drug screening
- L13 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI DNA microarray analysis of gene expression in the diagnosis of estrogen receptor positive- and negative-breast cancer
- L13 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiles for diagnosing renal cell carcinoma and other solid tumors

L13 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Human tissue-specific housekeeping genes identified by expression profiling

L13 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers from gene expression profiles

L13 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene expression in the retina and optic nerve in retinal degeneration and the diagnosis and treatment of the disease

L13 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene expression profiles and biomarkers for the detection of Chagas disease and other disease-related gene transcripts in blood

L13 ANSWER 34 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 TI New protein array comprising a surface having spatially defined locations containing drug metabolizing enzymes, examining gender and ethnicity-related differences in drug metabolism or cytotoxicity of drug metabolites

L13 ANSWER 35 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 TI Producing amplification target circles, by incubating binding guide conjugate that bind to analyte and half circle probes to promote ligation of half circle probes by guide oligonucleotide of conjugate that is complementary to probe

L13 ANSWER 36 OF 49 MEDLINE on STN DUPLICATE 4
 TI Two WXXF-based motifs in NECAPs define the specificity of accessory protein binding to AP-1 and AP-2.

L13 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Oligonucleotide probes and primers for diagnosing and monitoring autoimmune and chronic inflammatory diseases

L13 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene profiling methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets

L13 ANSWER 39 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 TI New dendritic cell-specific polynucleotide comprising e.g. a myosin phosphatase target subunit 1, a CD20-like precursor, a Ig superfamily protein or a 5-lipoxygenase activating protein gene, useful in modulating T cell immunity

L13 ANSWER 40 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 TI New array comprising surface having an attached cytosolic accessory protein free of its membrane protein components or other sub-units, useful for measuring the relative catalytic activity of accessory proteins

L13 ANSWER 41 OF 49 MEDLINE on STN DUPLICATE 5
 TI Increased expression of the SNARE accessory protein Munc18c in lipid-mediated insulin resistance.

L13 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Endocrine disruptor screening using DNA chips of endocrine disruptor-responsive genes

L13 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Global analysis of Helicobacter pylori gene expression in human gastric mucosa

L13 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Transcriptional and proteomic analysis of a ferric uptake regulator (fur) mutant of Shewanella oneidensis: possible involvement of fur in energy metabolism, transcriptional regulation, and oxidative stress

L13 ANSWER 45 OF 49 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
 TI Effects of HIV-1 Nef on cellular gene expression profiles.

L13 ANSWER 46 OF 49 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 TI Detecting analytes, useful in microscale protein expression profiling or in profiling peptides, comprises associating an analyte with a reporter binding primer, which mediates rolling circle replication of a circular DNA

L13 ANSWER 47 OF 49 MEDLINE on STN DUPLICATE 6
 TI Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention.

L13 ANSWER 48 OF 49 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
 TI DAP12: A key accessory protein for relaying signals by Natural Killer cell receptors.

L13 ANSWER 49 OF 49 MEDLINE on STN DUPLICATE 7
 TI CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.

=> d ibib abs l13 15,36,41,49

L13 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:301239 CAPLUS
 DOCUMENT NUMBER: 144:346343
 TITLE: Arrays of human proteins and their use for identifying binding proteins and enzyme substrates
 INVENTOR(S): Schweitzer, Barry; Ball, James A.; Predki, Paul; Michaud, Gregory A.; Zhou, Fang X.
 PATENT ASSIGNEE(S): Protometrix, Inc., USA
 SOURCE: PCT Int. Appl., 175 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006033972	A2	20060330	WO 2005-US32981	20050915
WO 2006033972	A9	20060427		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM
 US 2006223131 A1 20061005 US 2005-229258 20050915
 EP 1794589 A2 20070613 EP 2005-814077 20050915
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU

PRIORITY APPLN. INFO.:

US 2004-610444P P 20040915
 US 2004-610446P P 20040915
 US 2004-620193P P 20041018
 US 2004-620233P P 20041018
 US 2005-653585P P 20050215
 US 2005-665486P P 20050325
 WO 2005-US32981 W 20050915

AB The present invention provides human protein arrays that include 100-5000 human proteins. A method for identifying a substrate of an enzyme is disclosed. The method comprises contacting the enzyme with a positional addressable array comprising at least 100 proteins immobilized on a functionalized glass surface, and identifying a protein on the positional addressable array that is bound and/or modified by the enzyme, wherein a binding or modifying of the protein by the enzyme indicates that the protein is a substrate for the enzyme. A similar method for identifying proteins binding to the array is further disclosed. In addnl. embodiments, provided herein are methods for making an array of human proteins under non-denaturing conditions, including human proteins that are difficult to express and/or difficult to isolate in a non-denatured state.

L13 ANSWER 36 OF 49 MEDLINE on STN DUPLICATE 4
 ACCESSION NUMBER: 2004485857 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 15359277
 TITLE: Two WXXF-based motifs in NECAPs define the specificity of accessory protein binding to AP-1 and AP-2.
 AUTHOR: Ritter Brigitte; Denisov Alexei Yu; Philie Jacynthe; Deprez Christophe; Tung Elaine C; Gehring Kalle; McPherson Peter S
 CORPORATE SOURCE: Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
 SOURCE: The EMBO journal, (2004 Oct 1) Vol. 23, No. 19, pp. 3701-10. Electronic Publication: 2004-09-09. Journal code: 8208664. ISSN: 0261-4189.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200506
 ENTRY DATE: Entered STN: 30 Sep 2004
 Last Updated on STN: 22 Jun 2005
 Entered Medline: 21 Jun 2005

AB The adaptor proteins AP-2 and AP-1/GGAs are essential components of clathrin coats at the plasma membrane and trans-Golgi network, respectively. The adaptors recruit accessory proteins to clathrin-coated pits, which is dependent on the adaptor ear domains engaging short peptide motifs in the accessory proteins. Here, we perform an extensive mutational analysis of a novel WXXF-based motif that functions to mediate the binding of an array of accessory proteins to the alpha-adaptin ear domain of AP-2. Using nuclear magnetic resonance and mutational studies, we identified WXXF-based motifs as major ligands for a site on the alpha-ear previously shown to bind the DPW-bearing proteins epsin 1/2. We also defined the determinants that allow for specific binding of the alpha-ear motif to AP-2 as compared to those that allow a highly related WXXF-based motif to bind to the ear domains of AP-1/GGAs.

Intriguingly, placement of acidic residues around the WXXF cores is critical for binding specificity. These studies provide a structural basis for the specific recruitment of accessory proteins to appropriate sites of clathrin-coated vesicle formation.

L13 ANSWER 41 OF 49 MEDLINE on STN DUPLICATE 5
ACCESSION NUMBER: 2003270185 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12700337
TITLE: Increased expression of the SNARE accessory protein Munc18c in lipid-mediated insulin resistance.
AUTHOR: Schlaepfer Isabel R; Pulawa Leslie K; Ferreira Luis D M C-B; James David E; Capell Warren H; Eckel Robert H
CORPORATE SOURCE: Department of Medicine, Division of Endocrinology, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
CONTRACT NUMBER: DK-26356 (NIDDK)
SOURCE: Journal of lipid research, (2003 Jun) Vol. 44, No. 6, pp. 1174-81. Electronic Publication: 2003-04-16. Journal code: 0376606. ISSN: 0022-2275.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200402
ENTRY DATE: Entered STN: 11 Jun 2003
Last Updated on STN: 12 Feb 2004
Entered Medline: 11 Feb 2004
AB Fatty acids inhibit insulin-mediated glucose metabolism in skeletal muscle, an effect largely attributed to defects in insulin-mediated glucose transport. Insulin-resistant mice transgenic for the overexpression of lipoprotein lipase (LPL) in skeletal muscle were used to examine the molecular mechanism(s) in more detail. Using DNA gene chip array technology, and confirmation by RT-PCR and Western analysis, increases in the yeast Sec1p homolog Munc18c mRNA and protein were found in the gastrocnemius muscle of transgenic mice, but not other tissues. Munc18c has been previously demonstrated to impair insulin-mediated glucose transport in mammalian cells in vitro. Of interest, stably transfected C2C12 cells overexpressing LPL not only demonstrated increases in Munc18c mRNA and protein but also in transcription rates of the Munc18c gene. To confirm the relevance of fatty acid metabolism and insulin resistance to the expression of Munc18c in vivo, a 2-fold increase in Munc18c protein was demonstrated in mice fed a high-fat diet for 4 weeks. Together, these data are the first to implicate in vivo increases in Munc18c as a potential contributing mechanism to fatty acid-induced insulin resistance.

L13 ANSWER 49 OF 49 MEDLINE on STN DUPLICATE 7
ACCESSION NUMBER: 92229410 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1373518
TITLE: CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.
AUTHOR: Carter R H; Fearon D T
CORPORATE SOURCE: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
CONTRACT NUMBER: AI-22833 (NIAID) AI-28191 (NIAID)
SOURCE: Science (New York, N.Y.), (1992 Apr 3) Vol. 256, No. 5053, pp. 105-7. Journal code: 0404511. ISSN: 0036-8075.
PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199205

ENTRY DATE: Entered STN: 7 Jun 1992

Last Updated on STN: 6 Feb 1998

Entered Medline: 20 May 1992

AB Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors. Coligation of the membrane protein CD19 with the antigen receptor of B lymphocytes decreased the threshold for antigen receptor-dependent stimulation by two orders of magnitude. B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. The B cell resolves its dilemma by having an accessory protein that enables activation when few antigen receptors are occupied.

=> d ibib abs 113 48

L13 ANSWER 48 OF 49 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999188370 EMBASE

TITLE: DAP12: A key accessory protein for relaying signals by Natural Killer cell receptors.

AUTHOR: Campbell K.S.; Colonna M.

CORPORATE SOURCE: K.S. Campbell, Fox Chase Cancer Center, Institute Cancer Research, 7701 Burholme Avenue, Philadelphia, PA 19111, United States

SOURCE: International Journal of Biochemistry and Cell Biology, (Jun 1999) Vol. 31, No. 6, pp. 631-636.

Refs: 17

ISSN: 1357-2725 CODEN: IJBBFU

PUBLISHER IDENT.: S 1357-2725(99)00022-9

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 026 Immunology, Serology and Transplantation
029 Clinical and Experimental Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 10 Jun 1999

Last Updated on STN: 10 Jun 1999

AB DAP12 is a 12 kDa transmembrane protein recently recognized as a key signal transduction receptor element in Natural Killer (NK) cells. It is a disulfide-linked homodimer that non-covalently associates with several activating receptors expressed on NK cells. Activation signals initiated through DAP12 are predicted to play strategic roles in triggering NK cell cytotoxicity responses toward certain tumor cells and virally infected cells. The cytoplasmic domain of DAP12 contains an Immunoreceptor Tyrosine-based Activation Motif (ITAM). Phosphorylation of ITAM tyrosines mediates associations with protein tyrosine kinases, which is a resonant feature of signalling through these motifs in T and B cell antigen receptors. In addition, its expression in other tissues, including dendritic cells and monocytes, suggests that DAP12 transduces ITAM-mediated activation signals for an extended array of receptors in those cells as well. Copyright (C) 1999 Elsevier Science Ltd.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

106.33

106.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.56

-1.56

FILE 'STNGUIDE' ENTERED AT 15:11:59 ON 23 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 16, 2007 (20071116/UP)..

=>

=> d his

(FILE 'HOME' ENTERED AT 14:55:49 ON 23 NOV 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, SCISEARCH, EMBASE, WPIDS' ENTERED AT
14:57:10 ON 23 NOV 2007

L1 0 CYTOSOL? (S) ACCESSORY 5N PROTEIN
L2 0 ACCESSORY 5N PROTEIN
L3 9969 ACCESSORY (S) PROTEIN
L4 70 CYTOSOL? (S) ACCESSORY (S) PROTEIN
L5 1773 MEMBRANE AND L3
L6 28 MEMBRANE AND L4
L7 12 DUP REM L6 (16 DUPLICATES REMOVED)
L8 731064 (ARRAY OR ?ARRAY)
L9 1 L4 AND L8
L10 0 L9 NOT L7
L11 197 L3 AND L8
L12 69 MEMBRANE AND L11
L13 49 DUP REM L12 (20 DUPLICATES REMOVED)
L14 0 REVIEW AND L13
L15 2 REVIEW AND L11
L16 2 DUP REM L15 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 15:11:59 ON 23 NOV 2007

=> e kozlowski-R?/au

'AU' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'STNGUIDE'

The indicated field code is not available for EXPAND in this
file. To see a list of valid EXPAND field codes, enter HELP
SFIELDS at an arrow prompt (=>).

=> fil medline biosis caplus scisearch embase wpids

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.62

108.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.56

FILE 'MEDLINE' ENTERED AT 15:28:19 ON 23 NOV 2007

FILE 'BIOSIS' ENTERED AT 15:28:19 ON 23 NOV 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:28:19 ON 23 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 15:28:19 ON 23 NOV 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:28:19 ON 23 NOV 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:28:19 ON 23 NOV 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=> e kozlowski-R?/au

E1	2	KOZLOWSKI ZDZISLAW JANUSZ/AU
E2	44	KOZLOWSKI ZYGMUNT/AU
E3	0 -->	KOZLOWSKI-R?/AU
E4	1	KOZLOWSKIC HENRYK/AU
E5	1	KOZLOWSKIEGO S/AU
E6	2	KOZLOWSKII/AU
E7	1	KOZLOWSKII A/AU
E8	1	KOZLOWSKII E A/AU
E9	1	KOZLOWSKIK/AU
E10	1	KOZLOWSKIK K A/AU
E11	1	KOZLOWSKIU JR V A/AU
E12	1	KOZLOWSKL S/AU

=> e kozlowski-Ro?/au

E1	2	KOZLOWSKI ZDZISLAW JANUSZ/AU
E2	44	KOZLOWSKI ZYGMUNT/AU
E3	0 -->	KOZLOWSKI-RO?/AU
E4	1	KOZLOWSKIC HENRYK/AU
E5	1	KOZLOWSKIEGO S/AU
E6	2	KOZLOWSKII/AU
E7	1	KOZLOWSKII A/AU
E8	1	KOZLOWSKII E A/AU
E9	1	KOZLOWSKIK/AU
E10	1	KOZLOWSKIK K A/AU
E11	1	KOZLOWSKIU JR V A/AU
E12	1	KOZLOWSKL S/AU

=> e kozlowski-Rolan?/au

E1	2	KOZLOWSKI ZDZISLAW JANUSZ/AU
E2	44	KOZLOWSKI ZYGMUNT/AU
E3	0 -->	KOZLOWSKI-ROLAN?/AU
E4	1	KOZLOWSKIC HENRYK/AU
E5	1	KOZLOWSKIEGO S/AU
E6	2	KOZLOWSKII/AU
E7	1	KOZLOWSKII A/AU
E8	1	KOZLOWSKII E A/AU
E9	1	KOZLOWSKIK/AU
E10	1	KOZLOWSKIK K A/AU
E11	1	KOZLOWSKIU JR V A/AU
E12	1	KOZLOWSKL S/AU

=> e kozlowski-Roland?/au

E1	2	KOZLOWSKI ZDZISLAW JANUSZ/AU
E2	44	KOZLOWSKI ZYGMUNT/AU
E3	0 -->	KOZLOWSKI-ROLAND?/AU
E4	1	KOZLOWSKIC HENRYK/AU
E5	1	KOZLOWSKIEGO S/AU
E6	2	KOZLOWSKII/AU
E7	1	KOZLOWSKII A/AU

E8	1	KOZLOWSKII E A/AU
E9	1	KOZLOWSKIK/AU
E10	1	KOZLOWSKIK K A/AU
E11	1	KOZLOWSKIU JR V A/AU
E12	1	KOZLOWSKL S/AU

=> d his

(FILE 'HOME' ENTERED AT 14:55:49 ON 23 NOV 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, SCISEARCH, EMBASE, WPIDS' ENTERED AT 14:57:10 ON 23 NOV 2007

L1	0	CYTOSOL? (S) ACCESSORY 5N PROTEIN
L2	0	ACCESSORY 5N PROTEIN
L3	9969	ACCESSORY (S) PROTEIN
L4	70	CYTOSOL? (S) ACCESSORY (S) PROTEIN
L5	1773	MEMBRANE AND L3
L6	28	MEMBRANE AND L4
L7	12	DUP REM L6 (16 DUPLICATES REMOVED)
L8	731064	(ARRAY OR ?ARRAY)
L9	1	L4 AND L8
L10	0	L9 NOT L7
L11	197	L3 AND L8
L12	69	MEMBRANE AND L11
L13	49	DUP REM L12 (20 DUPLICATES REMOVED)
L14	0	REVIEW AND L13
L15	2	REVIEW AND L11
L16	2	DUP REM L15 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 15:11:59 ON 23 NOV 2007

FILE 'MEDLINE, BIOSIS, CAPLUS, SCISEARCH, EMBASE, WPIDS' ENTERED AT 15:28:19 ON 23 NOV 2007

E KOZLOWSKI-R?/AU
E KOZLOWSKI-RO?/AU
E KOZLOWSKI-ROLAN?/AU
E KOZLOWSKI-ROLAND?/AU

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.43	118.80

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.56

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:31:50 ON 23 NOV 2007